These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

537 related items for PubMed ID: 30632129

  • 1. Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer.
    Kittai AS, Blank J, Graff JN.
    Oncology (Williston Park); 2018 Dec 17; 32(12):599-602, 604-6. PubMed ID: 30632129
    [Abstract] [Full Text] [Related]

  • 2. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.
    Greiman AK, Keane TE.
    Curr Urol Rep; 2017 Jun 17; 18(6):41. PubMed ID: 28417429
    [Abstract] [Full Text] [Related]

  • 3. Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.
    Clinton TN, Woldu SL, Raj GV.
    Expert Opin Pharmacother; 2017 Jun 17; 18(8):825-832. PubMed ID: 28480768
    [Abstract] [Full Text] [Related]

  • 4. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    Miki K, Sasaki H, Kido M, Takahashi H, Aoki M, Egawa S.
    BMC Cancer; 2016 Sep 01; 16(1):708. PubMed ID: 27586506
    [Abstract] [Full Text] [Related]

  • 5. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
    Van Poppel H, Klotz L.
    Int J Urol; 2012 Jul 01; 19(7):594-601. PubMed ID: 22416801
    [Abstract] [Full Text] [Related]

  • 6. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
    Sasaki H, Miki K, Tashiro K, Mori K, Urabe F, Fukuokaya W, Kimura T, Sato S, Takahashi H, Aoki M, Egawa S.
    Andrology; 2022 Feb 01; 10(2):270-278. PubMed ID: 34510814
    [Abstract] [Full Text] [Related]

  • 7. [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].
    Tschöpe C, Kherad B, Spillmann F, Schneider CA, Pieske B, Krackhardt F.
    Herz; 2016 Dec 01; 41(8):697-705. PubMed ID: 27083586
    [Abstract] [Full Text] [Related]

  • 8. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Beckmann K, Garmo H, Adolfsson J, Bosco C, Johansson E, Robinson D, Holmberg L, Stattin P, Van Hemelrijck M.
    Eur Urol; 2019 Apr 01; 75(4):676-683. PubMed ID: 30497883
    [Abstract] [Full Text] [Related]

  • 9. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.
    Conteduca V, Di Lorenzo G, Tartarone A, Aieta M.
    Crit Rev Oncol Hematol; 2013 Apr 01; 86(1):42-51. PubMed ID: 23092636
    [Abstract] [Full Text] [Related]

  • 10. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer.
    Kirby RS, Fitzpatrick JM, Clarke N.
    BJU Int; 2009 Dec 01; 104(11):1580-4. PubMed ID: 20053189
    [Abstract] [Full Text] [Related]

  • 11. Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies.
    Sciarra A, Busetto GM, Salciccia S, Del Giudice F, Maggi M, Crocetto F, Ferro M, De Berardinis E, Scarpa RM, Porpiglia F, Carmignani L, Damiano R, Artibani W, Carrieri G.
    Front Endocrinol (Lausanne); 2021 Dec 01; 12():695170. PubMed ID: 34194398
    [Abstract] [Full Text] [Related]

  • 12. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.
    Shore ND, Abrahamsson PA, Anderson J, Crawford ED, Lange P.
    Prostate Cancer Prostatic Dis; 2013 Mar 01; 16(1):7-15. PubMed ID: 22751146
    [Abstract] [Full Text] [Related]

  • 13. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
    Axcrona K, Aaltomaa S, da Silva CM, Ozen H, Damber JE, Tankó LB, Colli E, Klarskov P.
    BJU Int; 2012 Dec 01; 110(11):1721-8. PubMed ID: 22500884
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.